Mast launches new ceftazadime/avibactam Mastdiscs

Mast has announced the launch of two new additions to its Mastdiscs portfolio of antibiotic susceptibility test discs.

The ceftazadime/avibactam 10-4 and ceftazadime/avibactam 30-20 products are provided in cartridge format and compatible with the company's existing disc dispenser product, ensuring they can be easily integrated into laboratory workflows.

Ceftazidime is active against numerous clinically relevant Gram-negative bacilli including Pseudomonas aeruginosa, but is readily hydrolysed by many beta-lactamases, making it less effective against multi-drug resistant organisms.

The addition of avibactam solves this problem by inhibiting a variety of beta-lactamases, including class A, class C and some class D enzymes, allowing it to restore the in vitro efficacy of ceftazidime by giving it a longer half-life within the body.

As such, ceftazadime/avibactam can be used to inhibit class A and class C beta-lactamases such as extended-spectrum beta lactamases, Klebsiella pneumoniae-producing carbapenemases and cephalosporinases.

Mast said: "This novel compound combines ceftazidime and avibactam to provide a solution for the treatment of Gram-negative organisms that confer resistance to beta-lactam antibiotics and pose a considerable threat to public health."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.